HC Wainwright & Co. Maintains Buy on Zevra Therapeutics, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reaffirmed a Buy rating on Zevra Therapeutics (NASDAQ:ZVRA) and increased the price target from $10 to $15.
December 28, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zevra Therapeutics' Buy rating is maintained by HC Wainwright & Co., with a raised price target from $10 to $15, indicating a positive outlook on the stock.
The reaffirmation of a Buy rating combined with an increased price target typically signals analyst confidence in the company's future performance, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100